| Cord Blood America CEO Discusses Company Strategy in Interview (PR Newswire) Cord Blood America, Inc. , the umbilical cord blood stem cell preservation company, is focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally. us.rd.yahoo.com |
NeoStem Overreacts to Fear of Dilution M.E. Garza submits: If you don't follow the company closely, you may not realize the significance of Tuesday's news announcement from NeoStem (AMEX:NBS), but the details are definitely worth noting. NBS announced Tuesday that its Suzhou Erye pharmaceutical subsidiary in China passed government inspection by that country's State Food and Drug Administration and they will now be allowed to manufacture penicillin and cephalosporin powder for injection at the company's new manufacturing facility.Complete Story » seekingalpha.com |
EPA Focuses on Poor, Minorities The Environmental Protection Agency outlined a plan for placing special emphasis on the health of low-income and minority populations when drafting rules. online.wsj.com |
2 Year-End FDA Run-Up Stock Plays Mike Havrilla submits:Below are two small-cap stocks with expected FDA decisions by year-end and stock prices below $5 per share that I currently own as potential run-up plays with PDUFA action goal dates in late December for pending New Drug Applications (NDAs).On 8/30/10, Alimera Sciences (ALIM) was granted a priority (six-month) review for the ILUVIEN NDA that was filed 6/29/10 with expected FDA decision by 12/29/10, seeking approval for diabetic macular edema (DME). pSivida (PSDV) is due to receive $25M upon FDA approval + 20% profit sharing. In addition a MAA was filed for EU approval 7/8/10, and ALIM expects to complete the 3-year FAME study by year-end 2010 (this data not required for NDA), also expects to file a New Drug Submission (NDS) for Health Canada approval this month.Complete Story » seekingalpha.com |
Abbott Halts Sales of Weight-Loss Drug Abbott Laboratories said it is pulling prescription weight-loss drug Meridia from the U.S., Canadian and Australian markets at the request of health regulators on concerns the drug increases the risk of heart attacks and strokes. online.wsj.com |